ClinicalTrials.gg
RecruitingNCT06285708Updated Jun 29, 2026

Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD

An interventional study of Prolonged exposure in PTSD, Suicidal Ideation and Suicide, Attempted, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Planned enrollment
523rd of 1,491
100 · median 65
Started
2024
with 102 others
No phase
1,012 of 1,664
234 open now
Primary completion
2026-12
later than 97 of 402 live
Registered
1,416th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 523rd largest by planned enrollment of the 1,491 interventional ones that give a count, is one of 103 that started in 2024, is one of 1,012 with no phase, reaches primary completion later than 97 of the 402 other live ones, and was the 1,416th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

The long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. However, no studies to date have assessed their effectiveness when used in combination. In light of this knowledge gap, the primary objective of this study will be to test the effectiveness of PE augmented with CRP as compared to PE with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid PTSD.

Read the detailed description

Posttraumatic stress disorder (PTSD) is associated with a host of functional problems and negative outcomes, including occupational and marital dissatisfaction, violence, alcohol and substance abuse, and suicide. Cognitive behavioral treatments tend to be the most highly efficacious treatments for PTSD. Prolonged Exposure (PE) therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure, psychoeducation, and controlled breathing training. Preliminary evidence suggests that PE is associated with significant suicidal ideation (SI) reductions. Enhancing PE with procedures that have been shown to significantly reduce suicidal thoughts and behaviors could serve to further reduce suicide risk during and after treatment completion.

The long-term goal of this project is to prevent suicides among individuals diagnosed with PTSD by integrating trauma-focused therapies with suicide-focused interventions. The primary objective of this pilot project is to test the efficacy of PE when enhanced with a crisis response plan utilizing self-report, behavioral, and ecological assessment methods to compare treatment effects.

03

Conditions studied

  • PTSD
  • Suicidal Ideation
  • Suicide, Attempted
  • Trauma, Psychological
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current diagnosis of PTSD or subthreshold PTSD; ability to speak and understand the English language; and ability to complete the process.

Exclusion criteria

Exclusion Criteria:

  • Substance use disorder requiring medical management; imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and impaired mental status that precludes the ability to provide (e.g., intoxication, psychosis, mania).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Prolonged exposure with crisis response plan

    In the enhanced prolonged exposure condition, participants will complete a CRP instead of a safety plan. The CRP is another recommended standard care practice with suicidal patients that includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be administered during the first therapy session.

    Behavioral: Prolonged exposure

  • Active comparator
    Prolonged exposure with safety plan

    In the standard prolonged exposure condition, participants will complete a safety plan, a procedure that includes personal warning signs for a suicidal crisis, self-management strategies, sources of social support, and contact information for professional resources and crisis services within the participant's local community, as well as the National Suicide Prevention Lifeline phone number. As a recommended standard care practice with suicidal patients, the combination of PE and safety plan represents treatment as usual. The safety plan will be administered during the first therapy session.

    Behavioral: Prolonged exposure

Interventions

  • BehavioralProlonged exposure

    PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.

06

What researchers measure

Primary outcomes

  1. Beck Scale for Suicidal Ideation (SSI)

    19 item self-report assessment of suicidal ideation, range of scores is 0-57, higher score indicates higher suicidal ideation

    Time frame: During the first 3 weeks and through one year follow up

  2. Self-Injurious Thoughts and Behaviors Interview-Revised (SITBI-R)

    31 item self-report measure of suicidal thoughts and behavior

    Time frame: During the first 3 weeks and through one year follow up

  3. PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (PCL-5)

    20 item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. range is 0-80, higher score indicates higher PTSD symptoms

    Time frame: During the first 3 weeks and through one year follow up

Secondary outcomes

  1. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Self-Rated Level 1 Cross-Cutting Symptom Measure

    transdiagnostic measure of current mental health symptomatology. It is an adult measure that consists of 23 questions that assess 13 psychiatric domains, including depression, anger, mania, anxiety, somatic symptoms, suicidal ideation, psychosis, sleep problems, memory, repetitive thoughts and behaviors, dissociation, personality functioning, and substance use.

    Time frame: During the first 3 weeks and through one year follow up

  2. Interpersonal Needs Questionnaire (INQ) - Abbreviated

    self-report assessment of interpersonal factors (perceived burdensomeness and thwarted belongingness) that contribute to suicidal ideation.

    Time frame: During the first 3 weeks and through one year follow up

  3. Beck Hopelessness Scale (BHS) - Abbreviated

    A 5 item self-report assessment of hopelessness, range of scores is 0-10, higher scores indicate better outcome

    Time frame: During the first 3 weeks and through one year follow up

  4. Brief Suicide Cognitions Scale (SCS)

    6 item self-report assessment of thoughts related to suicidal ideation, range of scores is 0-30, higher score indicates worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  5. Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)

    self-report assessment of emotion regulation.

    Time frame: During the first 3 weeks and through one year follow up

  6. Monetary Choice Questionnaire (MCQ)

    a self-report assessment of impulsivity

    Time frame: During the first 3 weeks and through one year follow up

  7. Behavioral Inhibition Scale (BIS)

    a 7 item self-report assessment of punishment sensitivity, range 0-28, higher scores indicate worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  8. Behavioral Activation Scale (BAS)

    a 13 item self-report assessment of reward sensitivity, range 0-52, higher scores indicate worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  9. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 4 item self-report assessment of depression, range of scores 4-20, higher score indicates worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  10. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 4 item self-report assessment of anxiety, range of scores 4-20, higher scores indicate worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  11. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 4 item self-report assessment of social activity, range of scores is 4-20, higher score indicates worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  12. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 4 item self-report assessment of fatigue, range of scores is 4-20, higher scores indicate worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  13. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 4 item self-report assessment of sleep, range of scores is 4-20, higher scores indicate worse outcome

    Time frame: During the first 3 weeks and through one year follow up

  14. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 4 item self-report assessment of physical function, range of scores is 4-20, higher score indicates better outcome

    Time frame: During the first 3 weeks and through one year follow up

  15. Patient-Reported Outcomes Measurement Information System (PROMIS) Measures

    a 5 item self-report assessment of pain, range of scores 5-25, higher scores indicates worse outcome

    Time frame: During the first 3 weeks and through one year follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data available by request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 34 months is close to that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 29, 2024
StartActual
Feb 26, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06285708
Collaborators
United States Department of Defense, Congressionally Directed Medical Research Programs
Responsible party
Jaryd Hiser (Assistant Professor, Ohio State University) — Principal investigator
First posted
Feb 29, 2024
Start date
Feb 26, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 29, 2026

Study contacts

Jaryd Hiser, Ph.D.
Contact
jaryd.hiser@osumc.edu
614-814-0163
Jaryd Hiser, Ph.D.
principal investigator · Assistant Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion